Genetic Technologies Announces Q1 FY23 Quarterly Results and Investor Webinar Details

Rhea-AI Summary

Genetic Technologies Limited (NASDAQ: GENE; ASX: GTG) reported a significant 375% revenue increase to A$1.93 million for Q1 FY23, driven by its core brands: geneType, EasyDNA, and AffinityDNA. Cash receipts were A$2.06 million with a cash balance of A$7.95 million. The company announced strategic acquisitions to strengthen its direct-to-consumer channel and expanded commercialization efforts for its geneType multi-risk test. Partnerships with healthcare providers and the development of a pharmacy channel were highlighted, along with progress in the US market aimed at securing reimbursement for its tests.

Positive

• Revenue increased by 375% to A$1.93 million from Q1 FY22.
• Cash receipts totaled A$2.06 million, with a cash balance of A$7.95 million.
• Strategic acquisition enhances the direct-to-consumer channel.
• Accelerated commercialization for geneType multi-risk tests targeting over 10,000 GPs.
• Demonstrated clinical utility of geneType in breast cancer risk assessment.
• Partnerships with healthcare providers expanding market presence.

Negative

• Operating cash outflows were A$3.4 million, indicating a negative cash flow.

MELBOURNE, Australia, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health, wellness and serious disease has released its results for the quarter ended September 30, 2022 (Q1 FY23).

Q1 FY23 Highlights:

• Revenue from customers of A$1.93 million for the quarter, up 375% from prior corresponding period (Q1 FY22), highlighting commercial progress with revenues anchoring from GTG’s 3 key brands: geneType, EasyDNA, and AffinityDNA.
• Cash receipts of A$2.06 million with a cash balance of A$7.95 million as at September 30, 2022
• Strategic acquisition strengthens the direct-to-consumer channel for GTG, building on the incremental EasyDNA expansion opportunities recently announced (ASX July 14, 2022).
• Accelerated commercialisation plans for geneType multi-risk test, promoting to over 10,000 General practitioners (GPs) across Australia by leveraging Breast Cancer Awareness Month.
• Genetype clinical utility demonstrated by the peer review publication of Genetype for Breast Cancer in the Journal of Precision Medicine confirming GeneType Risk Test outperforms traditional risk assessments for breast cancer in identifying risk by up to nine times.
• Continued partnership with Siles Health, leading Obstetrics and Gynecology practice with nine clinics across Melbourne to enable immediate access, network growth, advocacy, and genetic counselling to support onboarding of new practices with genetic counselling services.
• Developing pharmacy channel for Multi-Test – offering pharmacist option to offer the test with Dr. Siles for clinical support
• Engaged Jody Fassina, Insight Strategies to build long-term pathway for Australian Federal Government support for reimbursement.
• Material progress in USA with Alva10 and large payer engagement - the team have 8 active conversations with large payers in the US and a number progressing toward pilot implementation.
• New USA business manager is making great progress with concierge medicine groups and independent doctor networks with lead-generating attendance planned at a number of conferences.

Commenting on the Company’s financial performance, Chief Executive Officer Simon Morriss said: “Genetic Technologies is growing consolidated revenue and has demonstrated our focus on commercialisation through our core business brands. GeneType, EasyDNA, and AffinityDNA accumulatively boost Genetic Technologies product base, as it begins an exciting chapter for GTG.

“In this quarter, GTG’s revenue was A$1.93million, up more than three times on the prior corresponding period. We have a strong pipeline of revenue-generating opportunities for geneType multi-risk test, a developing pharmacy channel for multi-risk tests, and a number of current initiatives to widen accessibility and the market presence of GTG’s products.

“We are also very pleased to have a large number of key opinion leader publications that have either been recently published or are soon to be published, demonstrating both important clinical validity and the utility of the geneType test. We see these papers true enablers of the multi-test.”

Commercialisation progress in Australia

In Australia, GTG accelerated commercial engagement plans with Healthcare professionals (HCPs) to develop the geneType Hubs. In October’s Breast Cancer Awareness 2022, GTG launched a targeted promotion “Beyond BRCA” to 10,000 GPs across Australia, highlighting the importance of screening for breast cancer risk beyond the BRCA mutation. BRCA mutation represents less than 10% of breast cancer in women. 85% of breast cancer is non-hereditary, sporadic. GeneType Breast Cancer Risk Assessment Test can assist in identifying the risk of breast cancer in these women. GTG’s recent partnership with MedLab Clinical Ltd to execute the Australian B2B strategy has enabled access to their team of 6 Medical Science Liaison personnel. This agreement combined with GTG’s virtual sales team, provided by Hahn Health, has enabled the promotion of the geneType suite of risk assessment tests to Australian medical practitioners. Currently GTG has evaluations underway in approximately 60 practices in Australia.

Furthermore, GTG continued expanding the geneType Hub through its partnership with Siles Health and leading Obstetrics and Gynecology Specialist, Associate Professor Charles Siles. The partnership provides GTG with immediate access to more than 1,000 referring primary care physicians and 15,000 patients annually. In addition, the partnership also offers GTG the opportunity to expand other products such as Carrier and NIPT Testing through Dr. Charles Siles' vast network.

Building a pathway for reimbursement and government support in Australia

In this quarter, GTG deployed Jody Fassina from Insight Strategies to provide strategic counsel and an engagement strategy with the Federal Government in Australia. Mr. Fassina has over 25 years of experience advising in public policy environments and assisting in key influencer stakeholder mapping. In addition, GTG has also engaged the Australian Government Department of Health and Aged care focusing on screening policy and building a feasible opening for Federal Government support for reimbursing risk assessment tests in the near future.

Commercialisation pathway for geneType multi-test in the US

GTG’s commercialisation pathway in the US is well underway, concentrating on the Business to Business (B2B) channel’s concierge medicine groups and gaining coverage from the US payer system. On 15 June 2022, GTG announced the completion of an independently developed and validated customizable Budget Impact Model (BIM) which was developed by the Company’s US consultant ALVA10. The BIM validated the implementation of geneType Breast Cancer Risk Assessment Test with the potential to provide US$1.4b of savings for US payers annually. The BIM provides an opportunity and engagement in discussions with US National payers potentially accelerating a reimbursement pathway for geneType Breast Cancer risk tests, and the other geneType risk assessment tests as a needed ‘Standard of Care’.

GTG has also engaged ALVA10 to support market access for the geneType breast cancer risk assessment test with US payers. To date, ALVA10 identified 30 payer targets with 9 active engagements and an expectation a number of these opportunities will onboard the geneType Breast Cancer Risk Assessment Test in the near future.

Additionally, GTG is widening licensing opportunities, engaging US laboratory providers that already have established doctor-patient networks.  

Growing revenue with widening distribution channels and product ranges from GTG

Revenue from customers for the quarter was A$1.93 million, an increase of 375% from Q1 FY22.

The operating cash outflows were A$3.4m, with cash receipts from customers amounting to A$2.06 million. Expenses incurred on cash basis during the quarter included staff cost of $1.9m and product manufacturing and operating cost of A$1.4m, associated with sales volume expected to increase further with the ongoing engagement plans and revenue-generating leads for both geneType and EasyDNA products.

During the quarter, the Company made payments to related parties of the entity and their associates amounting to A$118k. The payments comprised directors’ fees of A$52k and consulting fees to directors of A$66k.

Research and publication pipeline continues, demonstrating clinical validity and utility of geneType tests

The GTG’s science team continues to place emphasis on scientific publications and with a number of submitted papers accepted for publication in credible journals. These papers continue to validate geneType risk assessment testing as an effective tool for improving patient care and health outcomes.

In September 2022, GTG’s Dr. Erika Spaeth (Director of Clinical Affairs), Dr. Richard Allman (Chief Scientific Officer) and Dr. Gillian Dite (Senior Biostatistician) authored a paper published in the Journal of Precision Medicine entitled “Integrating Personalised Medicine into Preventative Care through Risk Stratification”. The paper highlights the importance of incorporating risk stratification in preventive care, and demonstrated that the geneType risk assessment test for breast cancer outperformed traditional risk assessment models, in some cases showing a ninefold improvement in identifying women at risk of breast cancer compared with standard of care models such as IBIS.

The following papers have either been or are being published:

• “A combined clinical and genetic model for predicting risk of ovarian cancer” in the European Journal of Cancer Prevention, pending publication.
• Nurses’ Health Study, awaiting Journal approval
• UK Biobank, finalizing for submission
• Budget Impact Model for US, finalizing for publication and completion of manuscripts
• “Integrating Personalised Medicine into Preventative Care through Risk Stratification” in Journal of Precision Medicine, which was recently announced to the ASX on 29 September 2022
  

Webinar details

An investor webinar will be hosted by Chief Executive Officer, Simon Morriss, to discuss the first quarterly results and activities and invite all to participate.

To register, please follow the link below:

Date: Friday Nov 4, 2022 (Thursday Nov 3, New York)
Time: 11:00 AEDT (8:00pm New York EDT)

Registration Link: https://us02web.zoom.us/webinar/register/WN_DfSoWT0oSZulRmqvhL5-7w

Authorised for release by the board of directors of Genetic Technologies Limited

Enquiries

Investor Relations
Dave Gentry
RedChip Companies Inc.
1-800-RED-CHIP (733-2447)
Or 407-491-4498
GENE@redchip.com

About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) was founded in 1989. A global leader in guideline driven genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. In addition to our patented GeneType polygenic based risk tests, our portfolio includes pharmacogenomics, Non-Invasive Prenatal Testing (NIPT), carrier screen testing, oncogenetic diseases, and pet care.

GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company’s patented Polygenic Risk Scores (PRS) platform is a proprietary risk stratification tool developed over the past decade integrating clinical and genetic risk delivering actionable outcomes for physicians and individuals. Sporadic disease occurs in people with no family history of that disease and with no inherited change in their DNA making the risk difficult to predict with traditional methods.

Leading the world in risk prediction in Oncology, Cardiovascular and Metabolic diseases. Genetic Technologies continues to develop a pipeline of risk assessment products. The recent introduction of geneType Multi-Risk test risk assessments in one test covering breast cancer, colorectal cancer, prostate cancer, ovarian cancer, coronary artery disease and Type-2 diabetes, first in class test can predict a person’s risk in up to 70% of annual mortalities and morbidities before onset. These tests along with integration of recently acquired DNA based products underpin a broad and complementary portfolio of genomic based tests creating a significant competitive advantage.

For more information, please visit www.genetype.com

Forward Looking Statements
This press release may contain forward-looking statements about the Company's expectations, beliefs or intentions regarding, among other things, statements regarding the expected use of proceeds. In addition, from time to time, the Company or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by the Company with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of the Company's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause the Company's actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause the Company's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements as detailed in the Company's filings with the Securities and Exchange Commission and in its periodic filings in Australia and the risks and risk factors included therein. In addition, the Company operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. The Company does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

FAQ

What were the key financial results for Genetic Technologies Limited (GENE) in Q1 FY23?

Genetic Technologies reported revenue of A$1.93 million, a 375% increase from the prior year, and cash receipts of A$2.06 million.

How much cash balance did Genetic Technologies have at the end of Q1 FY23?

The cash balance as of September 30, 2022, was A$7.95 million.

What strategic actions is Genetic Technologies taking to expand its market presence?

Genetic Technologies is focusing on strategic acquisitions, strengthening its direct-to-consumer channel, and enhancing partnerships with healthcare providers.

What is the significance of the geneType multi-risk test for Genetic Technologies (GENE)?

The geneType multi-risk test is crucial for commercialization efforts, targeting over 10,000 GPs and highlighting the importance of risk assessment beyond BRCA mutations.

Did Genetic Technologies experience any negative financial impacts in Q1 FY23?

Yes, the company reported operating cash outflows of A$3.4 million, indicating a negative cash flow situation.